Revumenib is now an FDA-approved treatment for adult and pediatric patients with relapsed/refractory KMT2A-rearranged acute ...

Clinical trials are a significant part of the drug development cycle. However, the process has remained unchanged in recent ...

As optimism for GLP-1 receptor agonists for weight loss has grown, so too has their use in children. Currently, liraglutide ...

Kennedy is Trump’s pick for health secretary, but he has a history of spreading misinformation about a range of issues.

Plummeting trust in vaccines could be lethal on its own. But there are also ways Trump’s nominee for Health and Human ...

Eyenovia said on Friday it will discontinue a late-stage study for its experimental drug-device combination to treat near-sightedness and cut about 50% of its workforce.

ABC News’ Phil Lipof speaks with law professor Anya Prince on how 23andMe’s recent layoffs and shuttering of its drug ...

New analysis from the DETECT-A study supports MCED testing as a complement to current guideline-recommended screening in lung ...

If confirmed as the HHS Secretary by the US Senate, RFK Jr will oversee federal agencies that dictate healthcare policy in ...

Put up against placebo in the phase 3 EMBARK trial, delandistrogene moxeparvovec (Elevidys) did not significantly improve ...

Kennedy has pledged to "return our health agencies to their rich tradition of gold-standard, evidence-based science." ...

The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.